ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis. [electronic resource]
Producer: 20010712Description: 989-90 p. digitalISSN:- 0887-6924
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Benzamides
- Blast Crisis -- pathology
- Drug Screening Assays, Antitumor
- Enzyme Inhibitors -- pharmacology
- Fusion Proteins, bcr-abl -- antagonists & inhibitors
- Humans
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- pathology
- Neoplasm Proteins -- antagonists & inhibitors
- Oncogene Proteins v-abl -- antagonists & inhibitors
- Phosphorylation -- drug effects
- Piperazines -- pharmacology
- Precursor Cell Lymphoblastic Leukemia-Lymphoma -- pathology
- Protein Processing, Post-Translational -- drug effects
- Pyrimidines -- pharmacology
- Substrate Specificity
- Tumor Cells, Cultured -- drug effects
No physical items for this record
Publication Type: Letter
There are no comments on this title.
Log in to your account to post a comment.